Literature DB >> 35334061

"SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series" comment.

Dimitrios Patoulias1, Christodoulos Papadopoulos2, Michael Doumas3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35334061     DOI： 10.1007/s11739-022-02974-2

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN： 1828-0447            Impact factor:   5.472


× No keyword cloud information.
  5 in total

1.  Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.

Authors:  David Z I Cherney; Claire C J Dekkers; Sean J Barbour; Daniel Cattran; Abdul Halim Abdul Gafor; Peter J Greasley; Gozewijn D Laverman; Soo Kun Lim; Gian Luca Di Tanna; Heather N Reich; Marc G Vervloet; Muh Geot Wong; Ron T Gansevoort; Hiddo J L Heerspink
Journal:  Lancet Diabetes Endocrinol       Date:  2020-07       Impact factor: 32.069

2.  The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Alexia Piperidou; Pantelis Sarafidis; Afroditi Boutou; Costas Thomopoulos; Charalampos Loutradis; Maria Eleni Alexandrou; Apostolos Tsapas; Asterios Karagiannis
Journal:  J Hypertens       Date:  2019-07       Impact factor: 4.844

3.  Prediction of cardiovascular disease mortality by proteinuria and reduced kidney function: pooled analysis of 39,000 individuals from 7 cohort studies in Japan.

Authors:  Masaharu Nagata; Toshiharu Ninomiya; Yutaka Kiyohara; Yoshitaka Murakami; Fujiko Irie; Toshimi Sairenchi; Katsuyuki Miura; Tomonori Okamura; Hirotsugu Ueshima
Journal:  Am J Epidemiol       Date:  2013-06-09       Impact factor: 4.897

Review 4.  Circulating biomarkers in diagnosis and management of cardiac amyloidosis: a review for internist.

Authors:  Federico Perfetto; Mattia Zampieri; Carlo Fumagalli; Marco Allinovi; Francesco Cappelli
Journal:  Intern Emerg Med       Date:  2022-03-24       Impact factor: 5.472
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.